Trial Profile
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms OPTIC
- Sponsors ARIAD Pharmaceuticals; Takeda Development Center Americas; Takeda Pharma
- 12 Dec 2023 Results of long-term 4-year update of efficacy and safety outcomes , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Oct 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 15 Jun 2023 Results of post hoc analysis (n=282) from the 3-year update of the Optic trial assessing the efficacy and safety of 3 starting doses of Ponatinib in patients with chronic-phase chronic myeloid leukemia, presented at the 28th Congress of the European Haematology Association.